Cardiovascular Pharmacotherapy Review

Cardiovascular pharmacotherapy forms the cornerstone of managing chronic conditions that affect millions. Mastering these drug classes is essential for optimizing patient outcomes, preventing complications like stroke and myocardial infarction, and navigating complex clinical guidelines.

Core Drug Classes: Mechanisms and Key Characteristics

Understanding mechanisms of action—how a drug produces its effect at the molecular level—is the first step to predicting its use, side effects, and interactions.

Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors are first-line for many conditions. ACE inhibitors (e.g., lisinopril, enalapril) block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. ARBs (e.g., losartan, valsartan) selectively block the angiotensin II receptor, providing similar benefits with a different side effect profile. While both lower blood pressure and reduce cardiac remodeling, a key distinction is that ACE inhibitors can cause a dry cough and angioedema due to bradykinin accumulation, whereas ARBs typically do not.

Beta-blockers (e.g., metoprolol, carvedilol) antagonize beta-adrenergic receptors. Their indications are broad: hypertension, heart failure, angina, and arrhythmias. They reduce heart rate, contractility, and cardiac output. It’s critical to differentiate non-selective agents (propranolol, affecting ${\beta }_1$ and ${\beta }_2$ receptors) from cardio-selective ones (metoprolol, primarily ${\beta }_1$). Never abruptly discontinue beta-blockers, as this can precipitate rebound tachycardia or hypertension.

Calcium channel blockers (CCBs) inhibit calcium influx into vascular smooth muscle and cardiac cells. Dihydropyridines (e.g., amlodipine, nifedipine) are potent vasodilators used for hypertension. Non-dihydropyridines (e.g., diltiazem, verapamil) have greater effects on cardiac conduction and contractility, making them useful for rate control in atrial fibrillation and angina, but they must be used cautiously in heart failure.

Diuretics promote fluid and electrolyte excretion. Thiazides (e.g., hydrochlorothiazide) are first-line for hypertension, causing moderate Na${}^{+}$ and Cl${}^{-}$ loss. Loop diuretics (e.g., furosemide) act on the ascending loop of Henle and are the mainstay for managing volume overload in heart failure. Potassium-sparing diuretics (e.g., spironolactone, eplerenone) antagonize aldosterone and are key in heart failure for mortality benefit. Monitoring parameters include electrolytes (especially potassium), renal function, and volume status.

Guideline-Based Treatment Algorithms

Effective therapy requires applying drug knowledge within structured, evidence-based frameworks. For hypertension, first-line treatment typically involves an ACE inhibitor, ARB, CCB, or thiazide diuretic. For Black patients, guidelines often recommend starting with a thiazide or CCB due to greater average efficacy. Combination therapy is frequently required, with common two-drug regimens including an ACE/ARB plus a CCB or diuretic.

In heart failure with reduced ejection fraction (HFrEF), the goal is to antagonize neurohormonal systems. The foundational regimen is a combination of four drug classes: 1) a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), 2) an ACE inhibitor or ARB (or an ARNI—angiotensin receptor-neprilysin inhibitor like sacubitril/valsartan), 3) a mineralocorticoid receptor antagonist (spironolactone/eplerenone), and 4) an SGLT2 inhibitor (dapagliflozin/empagliflozin). Dosing is critical: these agents must be titrated to target or maximally tolerated doses proven in clinical trials, not just started at a low dose.

For dyslipidemia, statins (HMG-CoA reductase inhibitors) are the cornerstone. Their mechanism of action involves inhibiting cholesterol synthesis in the liver, leading to upregulation of LDL receptors and increased clearance of LDL-C from the blood. Treatment intensity is guided by patient risk. High-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) are used for secondary prevention or high-risk primary prevention, aiming for a ≥50% reduction in LDL-C. Monitoring involves checking a lipid panel 4-12 weeks after initiation and assessing for myalgia and hepatic transaminase elevations.

Anticoagulants, Antiarrhythmics, and Critical Monitoring

Anticoagulants prevent thrombus formation. Warfarin, a vitamin K antagonist, requires frequent monitoring via the INR (International Normalized Ratio) and has numerous food and drug interactions. Direct oral anticoagulants (DOACs like apixaban, rivaroxaban, dabigatran) offer more predictable pharmacokinetics but require assessment of renal function (using CrCl) for dosing. Reversal agents exist for both: vitamin K and PCCs for warfarin, idarucizumab for dabigatran, and andexanet alfa for factor Xa inhibitors.

Antiarrhythmic drugs are organized by the Vaughan Williams classification. Class II are the beta-blockers discussed. Class III agents (e.g., amiodarone, sotalol) prolong the action potential. Amiodarone is highly effective but has a daunting side effect profile requiring monitoring: pulmonary toxicity, thyroid dysfunction, hepatic enzyme elevation, and corneal deposits. Always consider non-pharmacologic options like ablation first for many arrhythmias.

Key monitoring parameters and drug interactions span all classes:

• Renal Function: ACE/ARBs, diuretics, SGLT2 inhibitors, and DOACs all require monitoring of serum creatinine and potassium. A rise in Cr after starting an ACEi may indicate renal artery stenosis.
• Electrolytes: Diuretics can cause hypokalemia (loops/thiazides) or hyperkalemia (K${}^{+}$-sparing agents, ACE/ARBs).
• Cytochrome P450: Many cardiovascular drugs are substrates, inhibitors, or inducers. For example, amiodarone is a strong inhibitor of CYP3A4 and CYP2C9, which can increase levels of warfarin, statins, and many others, necessitating dose reductions.

Common Pitfalls

1. Treating Numbers, Not Patients: Automatically increasing antihypertensive doses for a single high reading can cause hypotension. Always assess adherence, technique, and contributing factors (e.g., NSAID use, excess dietary sodium) first.
2. Misapplying Beta-Blockers in Acute Heart Failure: While beta-blockers are cornerstone therapy for chronic HFrEF, they can acutely worsen decompensated heart failure and should generally not be initiated during an active exacerbation. They should be started when the patient is euvolemic and stable.
3. Incorrect DOAC Dosing: The most common error is failing to adjust the dose for renal function (using CrCl) or age. For example, apixaban dose is reduced to 2.5 mg BID in patients with at least two of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. Applying this incorrectly can lead to under-dosing or increased bleeding risk.
4. Overlooking Statin Intolerance: While myalgias are reported, true rhabdomyolysis is rare. A common pitfall is discontinuing statin therapy altogether. Strategies include rechallenging with the same or a different statin, using a lower dose, or employing alternate dosing (e.g., rosuvastatin twice weekly).

Summary

• RAAS inhibitors (ACEis, ARBs) and beta-blockers are foundational for hypertension and heart failure, but their mechanisms and key side effects (cough, hyperkalemia, bradycardia) differ.
• Modern HFrEF pharmacotherapy requires rapid sequential titration of a four-pillar regimen: a beta-blocker, an ACEi/ARB/ARNI, an MRA, and an SGLT2 inhibitor to target doses for mortality benefit.
• Statin intensity (high, moderate, low) is determined by patient risk category, with the goal of reducing LDL-C by ≥50% in highest-risk patients.
• Anticoagulant choice hinges on renal function, need for monitoring, and reversal agent availability; always calculate CrCl for DOAC dosing.
• Successful therapy depends on vigilant monitoring of renal function, electrolytes, and for drug-specific toxicities, while actively managing interactions through appropriate dose adjustments.